MDMA-assisted therapy (MDMA-AT) using pharmaceutical-grade MDMA in controlled clinical settings is a safe and efficacious treatment for PTSD. After three MDMA administrations supported by psychotherapy, 67%–71% of individuals with PTSD no longer meet diagnostic criteria, compared with 32%–48% for placebo-assisted therapy, and effects persist at long-term follow-up. Unlike recreational use, which is confounded by adulterants and lack of precautions, MDMA-AT uniquely induces prosocial effects of trust and self-compassion while maintaining cognitive clarity. The review distinguishes evidence from recreational and therapeutic settings, describes neurobiological mechanisms, clinical evidence, public health and policy considerations, and future research directions.
PTSD involves abnormalities in memory, and psychedelics may help treat it by affecting multiple memory systems. Most research has focused on fear conditioning and extinction, which are limited models. A review of 25 studies found that the acute effects of psychedelics can enhance extinction learning, which is impaired in PTSD, though they may also enhance fear conditioning. Post-acute effects may also boost extinction learning. PTSD and psychedelics both impair hippocampal-dependent episodic memory formation, but psychedelics may enhance cortical-dependent semantic learning, potentially helping integrate trauma memories and disrupt maladaptive beliefs. More research is needed on episodic memory consolidation, retrieval, and reconsolidation, and on post-acute effects across all memory phases.